Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB)

A. O'Donnell (Washington, DC, United States of America), I. Gonda (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), J. Froehlich (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), C. Haworth (Cambridge, United Kingdom)

Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM)
Session: The global impact of bronchiectasis and nontuberculous mycobacteria (NTM)
Session type: Poster Discussion
Number: 357
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. O'Donnell (Washington, DC, United States of America), I. Gonda (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), J. Froehlich (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), C. Haworth (Cambridge, United Kingdom). Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB). 357

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: